Statins and venous thromboembolism: The jury is still out

Angiology

Volumn 64, Issue 7, 2013, Pages 489-491

  Paraskevas, Kosmas I ^a   Nicolaides, Andrew N ^b   Mikhailidis, Dimitri P ^c  

^a Department of Clinical Biochemistry   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; APIXABAN; BETRIXABAN; COLESEVELAM; DABIGATRAN ETEXILATE; EZETIMIBE; FLOVAGATRAN; FONDAPARINUX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RIVAROXABAN; ROSUVASTATIN; WARFARIN;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYOPATHY; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 84883411154     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712467493     Document Type: Editorial

References (31)

1. Baglin T. Inherited and acquired risk factors for venous thromboembolism. Semin Respir Crit Care Med. 2012 ; 33 (2). 127-137
2. Nikolaou VS, Desy NM, Bergeron SG, Antoniou J. Total knee replacement and chemical thromboprophylaxis: current evidence. Curr Vasc Pharmacol. 2011 ; 9 (1). 33-41
3. Gomez-Outes A, Lecumberri R, Pozo C, Rocha E. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol. 2009 ; 7 (3). 309-329
4. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008 ; 6 (4). 237-239
5. Olivieri F, Mazzanti I, Abbatecola AM, et al. Telomere/Telomerase system: a new target of statins pleiotropic effect?. Curr Vasc Pharmacol. 2012 ; 10 (2). 216-224
6. Paraskevas KI, Mikhailidis DP, Roussas N, Giannoukas AD. Effect of antiplatelet agents, statins, and other drugs on vascular access patency rates. Angiology. 2012 ; 63 (1). 5-8
7. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol. 2012 ; 10 (1). 33-41
8. Iakovis P, Anyfantakis ZA, Limas C, Kroupis C, Degiannis D, Cokkinos DV. Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: effects of statin therapy. Angiology. 2011 ; 62 (1). 55-61
9. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001 ; 161 (11). 1405-1410
10. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000 ; 132 (9). 689-696
11. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002 ; 105 (25). 2962-2967
12. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost. 2004 ; 2 (5). 700-701
13. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol. 2004 ; 18 (4). 477-482
14. Ramcharan AS, Van Stralen KJ, Snoep KJ, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy and the risk of venous thrombosis. J Thromb Haemost. 2009 ; 7 (4). 514-520
15. Paraskevas KI, Bessias N, Perdikides TP, Mikhailidis DP. Statins and venous thromboembolism: a novel effect of statins?. Curr Med Res Opin. 2009 ; 25 (7). 1807-1809
16. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 ; 360 (18). 1851-1861
17. Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J. 2010 ; 31 (10). 1248-1256
18. Rahimi K, Bhala N, Kamphuisen P, et al. Effect of statins and venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med. 2012 ; 9 (9). e1001310
19. Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med. 2011 ; 124 (9). 852-859
20. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360 (9326). 7-22
21. Amarenco P, Bogousslavsky J, Callahan A, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 ; 355 (6). 549-559
22. Freeman DJ, Robertson M, Brown EA, et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatr. 2011 ; 11: 8
23. Rosendaal FR. Statins and venous thrombosis: a story too good to be true?. PLoS Med. 2012 ; 9 (9). e1001311
24. Rabinowich L, Steinvil A, Leshem-Rubinow E, et al. Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation [published online October 4, 2012]. Heart. 2012 ;:
25. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk?. Curr Med Res Opin. 2008 ; 24 (11). 3059-3062
26. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002 ; 288 (4). 455-461
27. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life [published online June 28, 2012]. Nutr Metab Cardiovasc Dis. 2012 ;:
28. Whayne TF. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology. 2011 ; 62 (5). 415-421
29. Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol. 2012 ; 10 (2). 257-267
30. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol. 2010 ; 8 (5). 632-637
31. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007 ; 23 (9). 2183-2192